Jacobson ME, Seshadri RS, Morimoto R, et al. Early intervention and disease modification in atopic dermatitis: the current state of the field and barriers to progress. J Eur Acad Dermatol Venereol. 2024;38(4):665–72. https://doi.org/10.1111/jdv.19699.

Article  CAS  PubMed  Google Scholar 

Pandey M, Bijal P, Salni D, Chirag D. A review on neurodegenerative disease: the race to develop disease modifying drugs for Alzheimer’s and Parkinson’s. Pharma Innov. 2025;14(9):1–9. https://doi.org/10.22271/tpi.2025.v14.i9a.26256.

Article  CAS  Google Scholar 

Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662–80. https://doi.org/10.1038/s41573-023-00735-0.

Article  CAS  PubMed  Google Scholar 

Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther. 2022;12(12):2653–68. https://doi.org/10.1007/s13555-022-00819-6.

Article  Google Scholar 

Bacci ED, Correll JR, Pierce EJ, et al. Burden of atopic dermatitis and unmet needs with existing therapies. J Dermatolog Treat. 2023;34(1):2202288. https://doi.org/10.1080/09546634.2023.2202288.

Article  CAS  PubMed  Google Scholar 

von Stülpnagel CC, Augustin M, Düpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166–84. https://doi.org/10.1111/jdv.17348.

Article  Google Scholar 

Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(Suppl. 7):3–16. https://doi.org/10.1111/jdv.18168.

Article  PubMed  Google Scholar 

Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131. https://doi.org/10.1016/j.xjidi.2022.100131.

Article  PubMed  PubMed Central  Google Scholar 

Haddad EB, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(7):1501–33. https://doi.org/10.1007/s13555-022-00737-7.

Article  PubMed  PubMed Central  Google Scholar 

Siegfried EC, Bieber T, Paller AS, et al. Clinical remission and off-treatment remission in infants and preschoolers with moderate-to-severe atopic dermatitis treated with dupilumab: preliminary data from an open-label extension study. Poster presented at the 10th Congress of the European Academy of Paediatric Societies (EAPS); 17–20 October, 2024; Vienna.

Siegfried EC, Bieber T, Paller AS, et al. Clinical remission and off-treatment remission in pediatric patients with moderate-to-severe atopic dermatitis treated with dupilumab: open-label extension study preliminary data. Poster presented at the 23rd European Society for Pediatric Dermatology (ESPD) Congress; 2–4 May, 2024; Kosice.

Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–43. https://doi.org/10.1001/jamadermatol.2019.3617.

Article  PubMed  PubMed Central  Google Scholar 

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–49. https://doi.org/10.1111/bjd.19574.

Article  CAS  PubMed  Google Scholar 

Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939–52. https://doi.org/10.1007/s40257-023-00806-3.

Article  PubMed  PubMed Central  Google Scholar 

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91. https://doi.org/10.1056/NEJMoa2206714.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–8. https://doi.org/10.1093/bjd/ljad022.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Bieber T, Eyerich K, et al. Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. J Dermatol Treat. 2026;37(1):2636417. https://doi.org/10.1080/09546634.2026.2636417.

Article  CAS  Google Scholar 

Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264–75. https://doi.org/10.1016/j.jaci.2024.10.031.

Article  CAS  PubMed  Google Scholar 

Guttman-Yassky E, Simpson E, Esfandiari E, et al. Rocatinlimab: a novel T-cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis. Dermatol Ther. 2025;15:3153–71. https://doi.org/10.1007/s13555-025-01492-1.

Article  Google Scholar 

Guttman-Yassky E, Bieber T, Gutermuth J, et al. Sustained on- and off-treatment disease control in patients with moderate-to-severe atopic dermatitis following 12-week open-label once-daily abrocitinib 200 mg: post-hoc analysis of the phase 3 JADE REGIMEN study. Skin. 2026;10(2):s732. https://doi.org/10.25251/v9pqj003.

Article  Google Scholar 

Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2025;134(2):144–50. https://doi.org/10.1016/j.anai.2024.09.022.

Article  CAS  PubMed  Google Scholar 

Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–66. https://doi.org/10.1016/j.jaci.2022.08.026.

Article  CAS  PubMed  Google Scholar 

Hill DA, Spergel JM. The atopic march. Ann Allergy Asthma Immunol. 2018;120(2):131–7. https://doi.org/10.1016/j.anai.2017.10.037.

Article  PubMed  PubMed Central  Google Scholar 

Choi UE, Deng J, Parthasarathy V, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol. 2025;92(4):732–40. https://doi.org/10.1016/j.jaad.2024.10.107.

Article  PubMed  Google Scholar 

Lee C, Chen M, Jeng M, et al. Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder. Medicine (Baltimore). 2016;95(39):e5005. https://doi.org/10.1097/MD.0000000000005005.

Article  PubMed  PubMed Central  Google Scholar 

Cameron S, Donnelly A, Broderick C, et al. Mind and skin: exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis. Allergy. 2024;79(1):26–36. https://doi.org/10.1111/all.15818.

Article  CAS  PubMed  Google Scholar 

Kern C, Wan J, LeWinn KZ, et al. Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study. JAMA Dermatol. 2021;157(10):1200–8. https://doi.org/10.1001/jamadermatol.2021.2657.

Article  PubMed  PubMed Central  Google Scholar 

Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3–12. https://doi.org/10.1016/j.anai.2020.08.002.

Article  CAS  PubMed  Google Scholar 

von Kobyletzki L, Henrohn D, Ballardini N, et al. Comorbidities in childhood atopic dermatitis: a population-based study. J Eur Acad Dermatol Venereol. 2024;38(2):354–64. https://doi.org/10.1111/jdv.19569.

Article  CAS  Google Scholar 

Wu D, Wu X-D, Zhou X, Huang W, Luo C, Liu Y. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis. Ann Transl Med. 2021;9(1):40. https://doi.org/10.21037/atm-20-4708.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fehr D, Van Hung H-T, Maintz L, et al. Deciphering the connection between atopic dermatitis and cardiovascular diseases: analysis of clinical associations and cardiometabolic proteins. Allergy. 2025. https://doi.org/10.1111/all.16588.

Article